Who’s Developing What in Global Biopharmaceuticals?

Date: September 22, 2008
Pages: 436
Price:
US$ 1,215.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: W4FD7CF4196EN
Leaflet:

Download PDF Leaflet

Who’s Developing What in Global Biopharmaceuticals?
A critical assessment of leading companies, their research, products, partners and performance

The biopharmaceutical R&D sector is taking an ever more important role in the minds of industry and investors. The potential to fundamentally alter treatment regimes and cure, rather than symptomatically treat, many life-threatening conditions grows greater, but questions remain:
  • Who are the companies that are leading development in this critical area?
  • What is their area of expertise?
  • How substantial is their current product line-up or pipeline projects?
  • With whom are they collaborating?
  • How can you assess their strengths and weaknesses?

Who’s Developing What in Global Biopharmaceuticals? is a new 475 page management guide to 50 significant companies working in the field. From their structure, through collaboration and detailed pipeline evaluation, the report provides an unmatchable window to the future biopharmaceutical corporate environment.

Important areas covered, where available, for each company include:
  • Key Personnel – List of key management
  • Company Overview
  • Milestones – Summary table of key events in the company’s history
  • R&D Pipeline – Products/research by phase and indication
  • Technology – Novel discovery/production technology platforms
  • Agreements – Who’s working with whom? Important alliances identified
  • Key Financial Data – Essential P&L/funding data
  • Appraisal & Evaluation – A critical assessment of the company’s platform, pipeline and corporate environment

Answering key questions such as...
  • With which major pharmaceutical companies is French company Evotec working, and on what?
  • Optimer Pharmaceuticals has eight products in development – what stage are they at and for what are they indicated?
  • What benefit has Astex Therapeutics’ Pyramid drug discovery platform brought to the company?

Affymax
Ambit Biosciences
Ambrx
Amylin Pharmaceuticals
Arana Therapeutics
ARCA biopharma
ARIUS Research
ARYx Therapeutics
Astex Therapeutics
BioVex
BioXell
Bruin Pharmaceuticals
Cellectis
CombinatoRx
Deltanoid Pharmaceuticals
Diatos
Evotec
FivePrime Therapeutics
Genmab A/S
Idenix Pharmaceuticals
Ikaria
Infinity Pharmaceuticals
Intercytex
Ironwood Pharmaceuticals
KAI Pharmaceuticals
Kalypsys
Kereos
Micromet
Molecular Insight Pharmaceuticals
Neuromed Pharmaceuticals
Novexel
NPS Pharmaceuticals
Optimer Pharmaceuticals
Palatin Technologies
PharmaMar
Prana Biotechnology
Replidyne
S*BIO
Sosei
Speedel Pharmaceuticals
Synta Pharmaceuticals
Syntaxin
Takara Bio
Theravance
Tranzyme Pharma
Trimeris
Trubion Pharmaceuticals
ViroPharma
WILEX
Xencor
AFFYMAX

Key Personnel
Company Overview
Milestones
R&D Pipeline
Affymax R&D Pipeline, August 2008
Haematology
Hematide
Other Indications
Innotide
Adeptide
Angiotide
Technology
Agreements
Takeda
EntreMed
Nektar
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

AMBIT BIO SCIENCES

Key Personnel
Company Overview
Milestones
R&D Pipeline
Ambit Biosciences R&D Pipeline, August 2008
Oncology
AC220
AC480
AURORA Kinase Inhibitors
BRAF Kinase Inhibitors
JAK2
ABL (T3 151)
Technologies
Kinase Profiling Platform
Agreements
Cephalon
Bristol-Myers S quibb
Medarex
AstraZeneca
GlaxoSmithKline
Roche
Pfizer
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

AMBRX

Key Personnel
Company Overview
Milestones
R&D Pipeline
Human Growth Hormone
ARX201
Technologies
ReCODE Technology
Patents
Agreements
Merck S erono
Eli Lilly
Roche
Merck & Co
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

AMYLIN PHARMACEUTICALS

Key Personnel
Company Overview
Milestones
Marketed Products
Metabolism
BYETTA (exenatide, AC2993 (synthetic exendin-4)) injection
SYMLIN (pramlintide acetate) injection
R&D Pipeline
Amylin Pharmaceuticals R&D Pipeline, August 2008
Metabolism
Diabetes
Obesity
Discontinued Products
Cardiology
AC3056
AC2592
Agreements
Eli Lilly
Alkermes
Nastech
PsychoGenics
Kelaroo
BioSeek
Xenome
Johnson & Johnson
Aventis
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

ARANA THERAPEUTICS

Key Personnel
Company Overview
Milestones
R&D Pipeline
Arana Therapeutics R&D Pipeline, August 2008
Autoimmune and Inflammatory Diseases
ART621
PMX53
Oncology
ART104
ART010
ART150
ART140
ART101
ART160
Technologies
Protein Engineering Platforms
Patents
Patent Families – Revenue Generating
Patent Families – Product Development
Agreements
Vegenics
AVEO Pharmaceuticals
CSL Limited
GlaxoSmithKline
Centocor
Abbott
EvoGenix Pty
Kyowa Hakko
greenovation B iotech
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

ARCA BIOPHARMA

Key Personnel
Company Overview
Milestones
R&D Pipeline
Cardiology
Bucindolol
Agreements
Laboratory Corporation of America Holdings
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

ARIUS RESEARCH

Key Personnel
Company Overview
Milestones
R&D Pipeline
ARIUS Research R&D Pipeline, August 2008
Oncology
CD44 Cancer Stem Cell Program/ARH460-16-2
Trop-2 Signal Transduction Program/AR47A6.4.2
CD59 Complement Inhibitor Program/AR36A36.11.1
CD9 Cancer Stem Cell Program/AR40A746.2.3
AR7BD-33-11A
Others
Technologies
Patents
Agreements
Centro de Immunologia M olecular (CIMAB)
Xerion Pharmaceuticals AG
PDL B ioPharma
Medarex
Oxford B ioMedica
Genentech
Takeda
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

ARYX THERAPEUTICS

Key Personnel
Company Overview
Milestones
R&D Pipeline
ARYx Therapeutics R&D Pipeline, August 2008
Gastrointestinal
ATI-7505
ATI-24,000
Cardiology
ATI-5923
ATI-2042
Antipsychotic
ATI-9242
Metabolism
ATI-20,000
Technologies
Drug Design Technology
Design and Synthesis of Ideal Metabolites
RetroMetabolic Engineering
Evaluation of Metabolism
Patents
Agreements
Procter & Gamble
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

ASTEX THERAPEUTICS

Key Personnel
Company Overview
Milestones
R&D Pipeline
Astex Therapeutics R&D Pipeline, August 2008
Oncology
AT7519
AT9283
AT9311
AT13387
AT13148
Technologies
Drug Discovery Platform

PYRAMID

Patents
Agreements
Technology
Cambridge Crystallographic Data Centre
Daresbury Analytical Research and Technology Service
Global Phasing
Rigaku/MSC
Daylight Chemical Information Systems
Maybridge
Product
Janssen Research Foundation
Aventis
Mitsubishi Pharma
AstraZeneca
Institute of Cancer Research and Cancer Research Technology
The Wellcome Trust, the Institute of Cancer Research, Cancer Research Technology and GlaxoSmithKline
Schering AG
Fujisawa Pharmaceutical
Boehringer Ingelheim
Novartis
Pfizer
University of Newcastle upon Tyne/Cancer Research Technology
GlaxoSmithKline
Janssen Pharmaceutica
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

BIOVEX

Key Personnel
Company Overview
Milestones
R&D Pipeline
BioVex R&D Pipeline, August 2008
Oncology
OncoVEX GM-CSF
Virology
ImmunoVEXHSV2
Patents
Agreements
Wyeth Pharmaceuticals
Merck & Co
National Institutes of Health
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

BIOXELL

Key Personnel
Company Overview
Milestones
R&D Pipeline
BioXell R&D Pipeline, August 2008
Urology
BXL628/Elocalcitol
Pain Relief
MNAC13
Musculoskeletal
BXL093
Inflammation
TREM-1
TREM Programme
BXL746
Technologies
The VD3 platform
MNAC13 Platform
The TREM platform
Agreements
Roche
Lay Line Genomics
Merck & Co
Galapagos/ProSkelia
Zambon
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

BRUIN PHARMACEUTICALS

Key Personnel
Company Overview
R&D Pipeline
Cardiology
D-4F
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

CELLECTIS

Key Personnel
Company Overview
Milestones
R&D Pipeline
Oncology
Meganucleases targeting p53
Meganucleases targeting XPC
Immunology
Meganuclease targeting IL2RG
Meganuclease targeting RAG1
Patents
Agreements
Artemis Pharmaceuticals
Deltagen
Nucleis
Fermentas
Diversa
Regeneron Pharmaceuticals
Murinus
Ascenion
Lexicon Genetics
Celliance
Xenogen B iosciences
Ozgene
Biogen Idec
AstraZeneca
Shire Pharmaceuticals
Celonic
Genentech
GlaxoSmithKline
Laboratoires S ervier
TransGenic
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

COMBINATORX

Key Personnel
Company Overview
Milestones
R&D Pipeline
CombinatoRx R&D Pipeline, August 2008
Immuno-inflammatory
CRx-102
CRx-139
Pain
CRx-170
Dermatology
CRx-191
CRx-197
Metabolism
CRx-401
Other Research Programmes
Technologies
Drug Discovery Platforms
Patents
Agreements
Sosei
Accelerate B rain Cancer Cure (ABC2)
The National Institutes of Allergy and Infectious Diseases
HenKan Pharmaceutical Company
Angiotech Pharmaceuticals
Bio*One Capital
Fovea Pharmaceuticals S A
Cystic F ibrosis F oundation Therapeutics
Cure Huntington's Disease Initiative
Charley’s F und/The Nash Avery F oundation
Spinal M uscular Atrophy F oundation (SM A F oundation)
SAIC - National Institute of Neurological Disorders and S troke
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

DELTANOID PHARMACEUTICALS

Key Personnel
Company Overview
Milestones
R&D Pipeline
Osteoporosis
2MD
Agreements
Abbott
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

DIATOS

Key Personnel
Company Overview
Milestones
R&D Pipeline
Diatos R&D Pipeline, August 2008
Oncology
DaunoXome
DTS-301
DTS-201
DTS-108
Technologies
Drug Development Platforms
Agreements
Gilead S ciences
MacroMed
Medarex
Université catholique de Louvain
Institut Pasteur
Servier
OctoPlus Technologies
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

EVOTEC

Key Personnel
Company Overview
Milestones
R&D Pipeline
Evotec R&D Pipeline, August 2008
Central Nervous S ystem
EVT 201
EVT 101
EVT 103
EVT 302
VR1 Antagonist Programme
P2X3 and P2X2/3 Antagonist Programme
B1 antagonists
H3 antagonists
BACE inhibitors
Inflammatory Disease
P2X7 Antagonist Programme
MK2 inhibitors
Oncology
Hsp90 inhibitors
Bcl-2, Bcl-xL and Mcl-1 inhibitors
Technologies
High-throughput S creening (HTS) Technology
EVOlution platform
Patents
Agreements
Boehringer Ingelheim
Roche
Cure Huntingdon’s Disease Initiative (CHDI)
Ono Pharmaceutical
InterMune
Takeda
Interprotein Corporation
Other Research Contracts
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

FIVEPRIME THERAPEUTICS

Key Personnel
Company Overview
Milestones
R&D Pipeline
FivePrime Therapeutics R&D Pipeline, August 2008
Oncology
FP-1039
FPT040
FPA005
FPT069
Metabolism
FPT038
Cardiology
FPT033/FPT057
Gastrointestinal
FPT042/FPT046
Immunology
FPT025
Technologies
Drug Discovery Platforms
Agreements
Gene Logic
Biosite
Boehringer Ingelheim
Centocor/Johnson & Johnson
Pfizer
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

GENMAB A/S

Key Personnel
Company Overview
Milestones
R&D Pipeline
Genmab R&D Pipeline, August 2008
Oncology
HuMax-CD4 (zanolimumab)
HuMax-CD20 (ofatumumab)
HuMax-EGFr (zalutumumab)
R1507
HuMax-IL8
HuMax-CD38
HuMax-CD32b
Autoimmune/Anti-inflammatory
HuMax-CD20 (ofatumumab)
AMG 714
HuMax-IL8
HuMax-TAC
Neurology
HuMax-CD20 (ofatumumab)
Dermatology
HuMax-IL8
HuMax-TAC
Respiratory
Roche 4
Virology
HuMax-HepC
Transplant Rejection
HuMax-TAC
Undisclosed Indications
Roche 2
Roche 3
Technologies
Antibody Discovery Engine
Antibody Centre of Excellence
UniBody
Patents
Agreements
Amgen
ACE B ioSciences
Bionomics
Cytokine PharmaSciences
Ganymed Pharmaceuticals
GlaxoSmithKline
Medarex
Merck S erono
Roche
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

IDENIX PHARMACEUTICALS

Key Personnel
Company Overview
Milestones
Marketed Products
R&D Pipeline
Idenix Pharmaceuticals R&D Pipeline, August 2008
Virology
IDX184
IDX899
IDX375
IDX136/IDX316 Macrocyclic Protease Inhibitors
Discontinued Products
Valopicitabine/NM283
Patents
Agreements
Metabasis Therapeutics
Novartis Pharma
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

IKARIA

Key Personnel
Company Overview
Milestones
Marketed Products
R&D Pipeline
Ikaria R&D Pipeline, August 2008
Cardiology
INOMax
IK-1001
Immunology
Covox
Other Research Programmes
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

INFINITY PHARMACEUTICALS

Key Personnel
Company Overview
Milestones
R&D Pipeline
Infinity Pharmaceuticals R&D Pipeline, August 2008
Oncology
Retaspimycin
IPI-493
IPI-926
Bcl-2 Protein Inhibitors
Technologies
Diversity Oriented S ynthesis Technologies
Patents
Agreements
MedImmune/AstraZeneca
Novartis
Amgen
Johnson & Johnson
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

INTERCYTEX

Key Personnel
Company Overview
Milestones
R&D Pipeline
Intercytex R&D Pipeline, August 2008
Dermatology
ICX-PRO (cyzact)
VAVELTA
ICX-TRC
ICX-SKN
Technologies
Agreements
Baxter Healthcare
The Automation Partnership
Armed F orces Institute of Regenerative M edicine
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

IRONWOD PHARMACEUTICALS

Key Personnel
Company Overview
Milestones
R&D Pipeline
Ironwood Pharmaceuticals R&D Pipeline, August 2008
Gastrointestinal
MD-1100/linaclotide
Cardiology
MD-0727
Agreements
Forest Laboratories
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

KAI PHARMACEUTICALS

Key Personnel
Company Overview
Milestones
R&D Pipeline
KAI Pharmaceuticals, August 2008
Cardiology
KAI-9803
KAI-1455
Pain M anagement
KAI-1678
Gamma PKC
Ophthalmology
Beta PKC
Inflammatory Disease
Theta PKC Inhibition
Agreements
Sankyo
Bristol-Myers S quibb
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

KALYPSYS

Key Personnel
Company Overview
Milestones
R&D Pipeline
Kalypsys R&D Pipeline, August 2008
Metabolism
KD3010
KD3020
Pain
KD7040
Oncology
KD5170
Technologies
Agreements
Merck & Co
CV Therapeutics
Los Alamos National Laboratory
National Institutes of Health
NovImmune
Eidogen-Sertanty
Alcon
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

KEREOS

Key Personnel
Company Overview
Milestones
R&D Pipeline
Kereos R&D Pipeline, August 2008
Oncology
KI-0001
KI-100X
KM-4419
Cardiology
KI-0002
KI-1004
Technologies
Ligand-Targeted Emulsion Technologies
Agreements
Philips
Lantheus M edical Imaging (Bristol-Myers S quibb M edical Imaging)
Dow Chemical
Washington U niversity
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

MICROMET

Key Personnel
Company Overview
Milestones
R&D Pipeline
Micromet R&D Pipeline, August 2008
BiTE Antibody Only Pipeline
Oncology
MT103/MEDI-538
Adecatumumab (MT201)
MT293 (D93/TRC093)
MT110
MT111
MT228 (MORAb-028)
bscEphA2xCD3
muS110
Antibodies targeting CD33 and MCSP
Inflammatory/Autoimmune Diseases
MT203
MT204
Technologies
BiTE (Bispecific T-Cell Engagers) Technology
Single Chain Antibodies
Patents
Agreements
Enzon Pharmaceuticals
Abbott, Alligator B ioscience AB, Haptogen and A N Other
Cambridge Antibody Technology (CAT)
ESB ATech AG
MedImmune
Serono
EvoGenix Pty
Novuspharma S pA
TRACON Pharmaceuticals
Morphotek
Nycomed
University of S outhern California
Applied M olecular Evolution/Eli Lilly
Arizeke Pharmaceuticals
Antigenics
Viventia B arbados
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

MOLECULAR INSIGHT PHAR MACEUTICALS

Key Personnel
Company Overview
Milestones
R&D Pipeline
Molecular Insight R&D Pipeline, August 2008
Oncology
Azedra
Onalta
Solazed
Trofex
Cardiology
Zemiva
MIP-190
Neurology
MIP-170D
Technologies
Ultratrace Technology
SAAC Technology
SAACQ Technology
Nanotrace Discovery
Patents
Agreements
Bayer S chering Pharma
Novartis Pharma
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

NEUROMED PHARMACEUTICALS

Key Personnel
Company Overview
Milestones
R&D Pipeline
Neuromed Pharmaceuticals Pipeline, August 2008
Pain
NMED-160
NMED-1077
Others
Other Indications
Agreements
Merck & Co
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

NOVEXEL

Key Personnel
Company Overview
Milestones
R&D Pipeline
Novexel R&D Pipeline, August 2008
Antibacterial
NXL103
NXL101
NXL104
NXL105
Antifungal
NXL201
Agreements
Indevus Pharmaceuticals
Forest Laboratories
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

NPS PHARMACEUTICALS

Key Personnel
Company Overview
Milestones
R&D Pipeline
NPS Pharmaceuticals R&D Pipeline, August 2008
Gastrointestinal
GATTEX
Musculoskeletal
PREOS/Preotact
calcilytics
Central Nervous S ystem
NPSP156
Metabolism
NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection)
Renal
Cinacalcet HCl
Patents
Agreements
Amgen
Kirin Pharma
Nycomed
DRI Capital
GlaxoSmithKline
Janssen
AstraZeneca
Ortho-McNeil Pharmaceuticals
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

OPTIMER PHARMACEUTICALS

Key Personnel
Company Overview
Milestones
R&D Pipeline
Optimer Pharmaceuticals R&D Pipeline, August 2008
Antibacterial
OPT-80
Prulifloxacin (OPT-99)
OPT-1068/CEM-101
Musculoskeletal
OPT-88
Oncology
OPT-822/OPT-821
Technologies
Drug Discovery Platform
Patents
Agreements
C&O Pharmaceutical Technology (Holdings)
Par Pharmaceutical
Biocon
Nippon S hinyaku
Sloan-Kettering Institute for Cancer Research
Cempra Pharmaceuticals
The S cripps Research Institute
Inc Research
National Institute of Allergy and Infectious Diseases
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

PALATIN TECHNOLOGIES

Key Personnel
Company Overview
Milestones
R&D Pipeline
Palatin Technologies R&D Pipeline, August 2008
Cardiology
Bremelanotide
PL-6983
Natriuretic Receptor Compounds/PL-3994
Metabolism
Melanocortin-based Therapeutics
Imaging/Diagnosis
NeutroSpec
Technologies
Drug Development Platforms
MIDAS Drug Development Platform
NeutroSpec
Patents
Agreements
AstraZeneca
Mallinckrodt
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

PHARMAMAR

Key Personnel
Company Overview
Milestones
R&D Pipeline
PharmaMar R&D Pipeline, August 2008
Oncology
Yondelis (trabectedin)
Aplidin (plitidepsin)
PM02734
Kahalalide F
Zalypsis
Thiocoraline
Variolins
Lamellarins
Dermatology
Kahalalide F
Agreements
Johnson & Johnson
Innovex
Swedish Orphan International
Genesis Pharma
Cenit-Nanopharma Consortium
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

PRANA BIOTECHNOLOGY

Key Personnel
Company Overview
Milestones
R&D Pipeline
Prana Biotechnology R&D Pipeline, August 2008
Central Nervous S ystem
PBT2
Drug Candidate
Amyloid-inhibiting compounds
Immunotherapy
MAbs against Abeta
Oncology
PBT1/others
Ophthalmology
MPAC Compounds
Discontinued Products
Central Nervous S ystem
PBT1 (Clioquinol)
Patents
Agreements
Schering AG
Australian Industry Research and Development B oard
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

REPLIDYNE

Key Personnel
Company Overview
Milestones
R&D Pipeline
Replidyne R&D Pipeline, August 2008
Antibacterial
Faropenem medoxomil
REP3123/REP8839
DNA Replication Inhibitors Programme
Patents
Agreements
Forest Laboratories
Asubio Pharma
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

S*BIO

Key Personnel
Company Overview
Milestones
R&D Pipeline
Clinical Trials
HDAC
Kinase Programme
S*BIO R&D Pipeline, 2008
Technology
Agreements
A*STAR
Genome Institute of S ingapore
Karolinska Institutet
National U niversity Hospital, S ingapore
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

SOSEI

Key Personnel
Company Overview
Milestones
R&D Pipeline
Sosei R&D Pipeline, August 2008
Respiratory S ystem
NVA237
QVA149
Oncology
AD923
Central Nervous S ystem
AD337
SD118
Inflammation and Immunology
SD726
SD208
Women’s Healthcare
SOH-075
Agreements
Mundipharma
Sandoz
CombinatoRx
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

SPEEDEL PHARMACEUTICALS

Key Personnel
Company Overview
Milestones
R&D Pipeline
Speedel R&D Pipeline, August 2008
Cardiology
SPP100 (aliskiren,Tekturna, Rasilez)
SPP200 (pegmusirudin)
SPP301 (avosentan)
SPP600
SPP635
SPP676
SPP800 Series
SPP1100 Series
SPP2000 Series
Agreements
Locus Pharmaceuticals
Novartis
Roche
Abbott Laboratories
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

SYNTA PHARMACEUTICALS

Key Personnel
Company Overview
Milestones
R&D Pipeline
Synta Pharmaceuticals R&D Pipeline, August 2008
Oncology
STA-4783 (elesclomol)
STA-9090
STA-9584
STA-5312
Inflammatory Disease
STA-5326 (apilimod mesylate)
Crohn’s Disease
Rheumatoid Arthritis
Common Variable Immunodeficiency
Psoriasis
CRAC ion channel inhibitor
Technologies
Chemical Library
Screening Assays
In vivo Testing Capabilities
Chemistry Capabilities
Target Elucidation
Patents
Agreements
GlaxoSmithKline
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

SYNTAXIN

Key Personnel
Company Overview
Milestones
R&D Pipeline
Syntaxin R&D Pipeline, August 2008
Pain
Un-named Product
Respiratory
SYN187
Other
Endocrinology Products
Obesity Products
Nerve Disorder Products
Agreements
Allergan
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

TAKARA BIO

Key Personnel
Company Overview
Milestones
R&D Pipeline
Oncology
HSV-TK gene therapies
T-cell receptor (TCR) gene therapy
Cancer Immunotherapy
Cancer Immunity Reconstruction Therapy
Virology
VRX496
MazF Gene Therapy
Technologies
Research Reagents and S cientific Instruments
Contract Research S ervices
Agreements
InVivoScribe Technologies
Memorial S loan-Kettering Cancer Center
Peter M acCallum Cancer Centre
Green Cross Corporation
New England B iolabs
Transgenomic
Kemp B iotechnologies
Tianjin M edical U niversity
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

THERAVANCE

Key Personnel
Company Overview
Milestones
R&D Pipeline
Theravance R&D Pipeline, August 2008
Antibacterial
Telavancin
TD-1792
Respiratory
GW642444
GW685698
GSK159797
GSK1160724
GSK656398
GSK961081
Gastrointestinal
TD-5108
TD-2749
TD-6301
Patents
Agreements
Astellas
GlaxoSmithKline
AstraZeneca
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

TRANZYME PHARMA

Key Personnel
Company Overview
Milestones
R&D Pipeline
Tranzyme Pharma R&D Pipeline, August 2008
Gastrointestinal
TZP-101
TZP-102
TZP-201
TZP-301
Technologies
Drug Discovery Platform
Macrocyclic Template Chemistry (MATCH)
Patents
Agreements
Neokimia/Trimeris
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

TRIMERIS

Key Personnel
Company Overview
Milestones
Marketed Products
Virology
FUZEON
R&D Pipeline
Virology
FUZEON
TRI-1144
Patents
Agreements
Roche
Array B iopharma
Neokimia/Tranzyme
ChemBridge Research Laboratories
New Y ork B lood Center
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

TRUBION PHARMACEUTICALS

Key Personnel
Company Overview
Milestones
R&D Pipeline
Trubion Pharmaceuticals R&D Pipeline, August 2008
Autoimmune/Inflammatory Diseases
TRU-015
SBI-087
Oncology
TRU-015
TRU-016
Technologies
Product Engine
Patents
Agreements
Wyeth
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

VIROPHARMA

Key Personnel
Company Overview
Milestones
Marketed Products
Antibacterial
Vancocin
R&D Pipeline
ViroPharma R&D Pipeline, August 2008
Virology
Maribavir (CAMVIA)
CDI Programme
Anti-inflammatory
C1 inhibitor (human)
Discontinued Products
Virology
Picovir (Pleconaril)
Hepatitis C Candidates
HCV371
HCV-086
HCV-796
Patents
Agreements
GlaxoSmithKline
Sanofi-Synthélabo/sanofi-aventis
Schering-Plough
Eli Lilly
Wyeth
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

WILEX

Key Personnel
Company Overview
Milestones
R&D Pipeline
WILEX R&D Pipeline, August 2008
Oncology
WX-G250 and WX-G250RIT (RENCAREX)
WX-UK1
K931
WX-671 (MESUPRON)
CA9-SCAN (REDECTANE)
WX-77X Series
Patents
Agreements
Centocor
Bayer
VU University Medical Center Amsterdam
Fox Chase Cancer Center
Esteve
IBA M olecular
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

XENCOR

Key Personnel
Company Overview
Milestones
R&D Pipeline
Xencor R&D Pipeline, August 2008
Inflammatory Disease
XPro1595
Oncology
XmAb2513
Oncology/Inflammatory Disease
XmAb5574
XmAb5871
XmAb5485
Technologies
Protein Design Automation
XPro
XmAb technology
ImmunoPDA
Patents
Agreements
Caltech
Torrey M esa Research Institute
Protein Design Labs
Eli Lilly
Genentech
Chugai Pharmaceutical
Centocor
MedImmune
Roche
Boehringer Ingelheim
Human Genome S ciences
Key Financial Data
Appraisal & Evaluation
Platform, Pipeline, Products
Corporate Environment

ESPICOM ANALYSIS

Winners & Losers
Biopharmaceutical Company R&D Pipelines
Phase III Drug Candidates
Phase III Drug Candidates
Methodology
Company Ratings
Section Name
Skip to top


Who's Developing What in New Cancer Drugs? US$ 865.00 Nov, 2007 · 1500 pages
Who's Developing What in Cardiovascular Devices? US$ 1,040.00 Sep, 2010 · 412 pages
Who's Developing What in Cardiovascular Devices? US$ 1,040.00 Oct, 2009 · 432 pages
Who's Developing What in Drug Delivery 2009 US$ 1,040.00 Nov, 2009 · 830 pages

Ask Your Question

Who’s Developing What in Global Biopharmaceuticals?
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: